Over the last 7 days, the United States market has experienced a drop of 9.4%, contributing to a 3.4% decline over the past year, although earnings are forecast to grow by 14% annually. In this context, identifying high growth tech stocks involves looking for companies with strong fundamentals and innovative capabilities that can thrive despite current market challenges.

Top 10 High Growth Tech Companies In The United States

Click here to see the full list of 235 stocks from our US High Growth Tech and AI Stocks screener.

Here we highlight a subset of our preferred stocks from the screener.

Aurinia Pharmaceuticals

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Aurinia Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing therapies for autoimmune diseases with unmet medical needs in the United States, with a market cap of approximately $1.07 billion.

Operations: Aurinia Pharmaceuticals focuses on the research, development, and commercialization of therapeutic drugs for autoimmune diseases in the U.S., generating $235.13 million in revenue from these activities.

Aurinia Pharmaceuticals has demonstrated a robust turnaround, transitioning from a net loss of USD 78.02 million in the previous year to a net income of USD 5.75 million in 2024. This shift is underscored by an impressive annual revenue increase to USD 235.13 million, up from USD 175.51 million, reflecting an annual growth rate of 11.5%. The company's strategic share repurchase program further highlights its confidence in sustained growth, with over 6 million shares bought back for approximately $40.67 million last year alone. Looking ahead, Aurinia anticipates revenues reaching between $250 and $260 million in 2025, suggesting continued upward trajectory bolstered by effective R&D investments and operational enhancements.

• Unlock comprehensive insights into our analysis of Aurinia Pharmaceuticals stock in this health report.

• Understand Aurinia Pharmaceuticals' track record by examining our Past report.

Anavex Life Sciences

Simply Wall St Growth Rating: ★★★★★☆

Overview: Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company focused on developing therapeutics for central nervous system diseases in the United States, with a market cap of approximately $696.68 million.

Operations: Anavex Life Sciences focuses on developing therapeutics for central nervous system diseases in the U.S. The company is currently in the clinical stage and does not report revenue from its operations.

Anavex Life Sciences is making significant strides in Alzheimer's treatment with its drug blarcamesine, showing sustained clinical benefits in long-term studies. Recent results presented at the AD/PDTM 2025 Conference revealed that continuous treatment up to four years not only maintains patient cognition but also exhibits a favorable safety profile without severe side effects. This progress is underpinned by a robust R&D focus, as evidenced by their ongoing trials and detailed peer-reviewed publications which suggest blarcamesine's potential as an early intervention that could modify disease progression. With revenue growth forecasted at 54.2% annually and an anticipated shift to profitability within three years, Anavex’s strategic direction appears well-aligned with market expectations for high-growth biotech firms.

• Take a closer look at Anavex Life Sciences' potential here in our health report.

• Assess Anavex Life Sciences' past performance with our detailed historical performance reports.

Olo

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Olo Inc. operates an open SaaS platform for restaurants in the United States, with a market cap of $971.19 million.

Operations: The company's primary revenue stream comes from its Internet Software & Services segment, generating $284.94 million.

Olo, a tech firm specializing in streamlined food ordering and delivery solutions, has demonstrated resilience and adaptability in its business model. With a 15.7% annual revenue growth rate and an impressive turnaround from a net loss of $58.29 million last year to just $0.897 million this year, Olo's strategic initiatives are bearing fruit. The company's recent partnership with Waffle House to expand delivery services underscores its commitment to enhancing restaurant operations through technology. This move not only broadens its market reach but also fortifies its position within the competitive landscape of food service tech providers, promising robust future prospects as it aims for profitability within three years.

• Click to explore a detailed breakdown of our findings in Olo's health report.

• Examine Olo's past performance report to understand how it has performed in the past.

Next Steps

• Take a closer look at our US High Growth Tech and AI Stocks list of 235 companies by clicking here.
• Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports.
• Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free.

Ready For A Different Approach?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NasdaqGM:AUPH NasdaqGS:AVXL and NYSE:OLO.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com